Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
144.60
-7.88 (-5.17%)
At close: Nov 16, 2026, 4:00 PM EST
148.00
+3.40 (2.35%)
After-hours: Nov 16, 2026, 7:51 PM EST
← View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 10, 2026

Summary

Priority review sets a February 28, 2027 PDUFA date for QTORIN rapamycin in mLM, while launch preparation and center outreach advance. Pipeline plans include cVM Phase III before year-end 2026 and an angiokeratoma readout in H2 2027.

Annabel Samimy
Analyst, Stifel

Okay, I got it. All right. Good morning, everyone, and welcome to the Stifel Healthcare Conference. We are pleased to have Palvella with us, and Wes Kaupinen, who is the CEO of Palvella. Palvella, as you know, is developing the QTORIN or has a QTORIN platform in developing a number of programs in rare skin diseases and hopefully circling the wagons on, I think it was 600 rare skin diseases-

Wes Kaupinen
CEO, Palvella Therapeutics

That is right.

Annabel Samimy
Analyst, Stifel

-in dermatology. Welcome. Wes, maybe you can just start with giving us an overview of the business, describe the company, the QTORIN platform, how capital efficient you are in terms of developing these programs, just to level set everyone.

Wes Kaupinen
CEO, Palvella Therapeutics

Great. Well, thanks, Annabel. Great to be back with you here at the Stifel Conference for a second time. I will begin with the name Palvella. Palvella in Finnish means to serve, and so the mission of our company is to serve patients that have serious rare skin diseases and vascular anomalies which currently have no FDA-approved therapies. The vision for the company, Annabel alluded to it, is we want to build the enduring leader that is developing and commercializing therapies for patients suffering from serious rare skin diseases and vascular anomalies. Together, those two areas represent close to 700 diseases. Over 98% of those do not have a single approved treatment. This area is less competitive than other areas of orphan, like oncology and neurology. Our objective is to build the enduring leader in areas of high unmet need and low competitive intensity.

Our strategy can be summed up in a word, which is first. We are built to go from zero to one, take diseases that previously had nothing, and pioneer the first therapy for those patients and for those rare disease communities. The way that we are doing that is through, as Annabel alluded to, our QTORIN platform. This is a platform that allows us to reproducibly develop novel topical product candidates and then evaluate those product candidates in these rare skin diseases and vascular malformation where there is no approved treatments. There are three elements to QTORIN. That is our formulation expertise and topical formulation, it is our manufacturing know-how, and then applying a fit-for-purpose intellectual property strategy which allows us to generate long duration IP claims on each of our QTORIN product candidates. Capital efficiency, great to hear that capital efficiency is back in biotech. That really begins with a management philosophy.

Our philosophy at Palvella is to try to flush out as much risk on our programs on the smallest quantums of capital. We think that is the right approach to capital allocation. We have been that way since founding. We have recruited a senior leadership team, like Matt Korenberg, our CFO, our Chief Commercial Officer, Ashley Kline, Kathy Goin, our COO, Jeff Martini, our CSO, that shares that philosophy. Having an established platform in place certainly allows us to recognize capital efficiency as well. When we are bringing new programs into the platform because we have that existing formulation, manufacturing, and IP expertise, we believe we can go from concept to phase II data on much smaller quantums of capital compared to just starting programs de novo.

Annabel Samimy
Analyst, Stifel

Great. What is exciting about Palvella right now is that your first NDA has been accepted, breakthrough designation, fast-tracked with a four-month review. Maybe you can tell us what you think that means for FDA willingness to accept unique trial designs for rare diseases, and how applicable do you think this is to other rare skin diseases that you are looking at?

Wes Kaupinen
CEO, Palvella Therapeutics

Well, I think many of us in the rare disease space are really encouraged by this new framework that was recently announced by the FDA. I think there is a recognition by the new FDA leadership of the tremendous unmet need that still exists in rare disease. Our program, as you alluded to, we have been the beneficiary of multiple FDA designations, orphan designation, fast-track designation, which is designed to expedite therapies to patients. After our phase II data, we were granted breakthrough designation, and the FDA has also supported our mLM program with an FDA orphan product grant, which is non-dilutive capital that has been used to fund our phase III program and open-label extension study. Our most recent designations, we are following our pre-NDA meeting. We were granted rolling review of our NDA application, and just recently, at the end of October, we were granted FDA's priority review.

Because we are developing rapamycin, which is not a new molecular entity, there was a six-month priority review that was granted from the date of NDA submission. For us, that results in a PDUFA date on Rare Disease Day, which is February 28th of next year. We are all eyes forward at the company, focused on securing a timely approval, and we've made a strategic decision to really scale up our commercial and medical teams in advance of FDA approval such that we really want to have that commercial infrastructure in place several months ahead of the launch.

Annabel Samimy
Analyst, Stifel

Yeah. Let's talk about those commercial preparations because they seem pretty extensive and expansive for the stage. Why don't you talk to us about the preparations that you've done here?

Wes Kaupinen
CEO, Palvella Therapeutics

Sure. Thanks, Annabel. I'll begin with leadership. I think the success of the launch in a lot of ways is, yes, governed by the product profile, where we showed 95% of patients improving on the primary endpoint in phase III. We had 100% of patients improve on the clinical global impression of change in phase II. That's a foundational element of the launch success. But really, it's going to be the people who day-to-day are going to be working with physicians, working with payers, and in our case, working directly with patients through our patient access liaison team, that will ensure that this launch is very successful for the mLM community, and specifically those patients who are suffering from microcystic lymphatic malformations. On the leadership side, we hired Ashley Kline as our Chief Commercial Officer. She was able to be on her first earnings call just last week.

This is not Ashley's first orphan launch. She previously launched a drug called OXERVATE, which is a topical therapy for neurotrophic keratitis, previously a rare disease with no approved therapies. She brought that drug to market very successfully, and now does over $1 billion in sales annually. Ashley brings tremendous experience as a proven orphan commercial launch leader. We also have recruited others in our organization with rare disease experience, but also dermatology experience. One of the primary treaters of microcystic lymphatic malformations will be dermatologists, so we've been able to bring on Jen McDonough as our Head of Market Access and Reimbursement. Jen previously had a very similar role at Krystal Biotech, played a major role in their success launching VYJUVEK for patients with epidermolysis bullosa. Kent Taylor has been brought on as our Head of Sales.

Kent was previously at Arcutis, leading the sales organization there, helping to launch ZORYVE very successfully. We've also brought on the next layer of leadership on Kent's team, bringing on very strong area Vice Presidents as well as rare disease Directors. Our goal is to bring on the best of dermatology and rare disease experience, folks who are proven high performers, very entrepreneurial, and want to win for patients. One of the major thrusts we've been making with this new team that we have in place is have our team out in the field day in and day out, week in and week out, meeting with physicians, meeting with vascular anomaly centers. There's about 400 centers in the United States that have about half of this market, or 15,000 patients. Our goal is to be out meeting all of those centers prior to FDA approval next February.

We've met with over 200 of those centers to date, and we'll meet with more this week, and really pleased with the quality of the work that our team is doing.

Annabel Samimy
Analyst, Stifel

Great. Ashley shared with us on the earnings call one of the surveys that you all had done to identify where the prescribers are. Can you talk a little bit about that, where they sit, how it's possibly changed your assumptions of either the market size, the treating population, and what can you share with us there?

Wes Kaupinen
CEO, Palvella Therapeutics

Sure. New market research data that Ashley Kline presented last week, we did a survey of about 150 physicians in the United States. Over 70% indicated that upon FDA approval, they would prescribe QTORIN rapamycin within three months of approval, and then over three-quarters indicated that they would prescribe QTORIN rapamycin for more than one microcystic lymphatic malformation patient. This is really encouraging market research data. I found that best practice is to always try to marry what you're seeing in third-party market research with what you're hearing in the field. Our medical affairs team and our commercial team, and being at medical congresses, and also being at the vascular anomaly centers, is hearing similar positive feedback. In terms of patient identification, this is a different sort of rare disease market than most that I've worked in over the last approximately 15 years.

The reason that it's different is that there is a large concentration of diagnosed patients that are in a handful of vascular anomaly centers and other high-volume centers in the United States. With a lot of orphan launches, there is significant market development and market organization work that needs to be done, particularly in first-in-disease launches. What's different here with microcystic lymphatic malformations is over the last two decades, academic medicine has organized vascular anomaly centers in recognition of the seriousness of these complex vascular malformations. These centers are in place across the United States, and what we've seen through claims data is that they have very large patient loads. We're going to be able to go out to about 400 centers that represent 15,000 patients.

Again, those patients are diagnosed and within clinical medicine, a little bit different than a lot of orphan launches, where you're going out and doing the patient identification work, trying to bring that patient to clinical medicine, undergoing a genetic test, and then trying to generate the script for the patient. We think there's some efficiencies to this market relative to other orphan market launches.

Annabel Samimy
Analyst, Stifel

Okay. I'm going to touch on one thing that you've been asked many, many times, which is you see a patient population of greater than 30,000, but additional epidemiological studies have pointed to potentially 95,000 patients out there. Can you talk about that? Why disparity in the potential prevalence of disease and how you narrow down on your greater than 30,000 versus the 95,000?

Wes Kaupinen
CEO, Palvella Therapeutics

Sure.

Annabel Samimy
Analyst, Stifel

How do you get to that 95,000?

Wes Kaupinen
CEO, Palvella Therapeutics

Sure. Makes sense. We estimate there's greater than 30,000 diagnosed, in spite of some of these, the published work that indicates there could be more. We think that in rare disease epidemiology, there's always error bars. It's not totally precise, and I think best practice is to try to triangulate on what the size of the market is. We've used a number of different methods. We've done claims analyses, we've done real-world occurrence studies, we've done field checks to try to size this market. There are multiple publications that are out there and posters indicating a larger market. There's a study that was done, that's published in Orphanet, under Gallagher in 2022, that estimates there's about 80,000 diagnosed patients that have microcystic manifestations of their lymphatic malformations. Claims data says 45 to 95. We think that 30,000 could prove over time to be a conservative estimate.

Our goal as a company is to go out and create a lot of disease state awareness such that we improve diagnosis, and then if we're FDA approved, hopefully have the opportunity to dramatically improve treatment, with a drug that we think is on target, hitting that causal biology, and doing so in the pathogenic tissue of interest. Expect to see a very heavy medical affairs presence from Palvella at medical congresses. Encourage everyone that's listening to opt into our BEYOND mLM disease state awareness campaign. That's our digital campaign to really elevate the awareness of this disease. But I think, Annabel, to your point, over time, once the drug becomes approved and we continue to push these medical education initiatives, some previous rare disease studies would show that these markets can improve or can grow over time.

Annabel Samimy
Analyst, Stifel

Going back to Ashley's survey about physician willingness to prescribe, I'm going to maybe botch these numbers. 70% said they would prescribe within three months, 75% said several patients right away. Okay, I got it right then. What does that mean for how you view the launch trajectory of the drug?

Wes Kaupinen
CEO, Palvella Therapeutics

Sure. I think what we've seen through all of our market research, this most recent wave and then previous market research that we've done, is we anticipate very strong demand for the product, and that's based on a few things. Number one, it's a serious, rare, chronically debilitating disease where there's currently no FDA-approved therapies. These patients urgently need to be treated. The disease has been shown to be proliferative and progressive. These patients can experience things like lymphorrhea, leaking, infection, bleeding, hospitalization. A lot of the demand is driven by that unmet need that exists today. It's also driven by our product profile in terms of what we showed in our phase III and phase II study. As we think about the adoption curve and the revenue curve, I think it's instructive to look at other first-in-disease launches.

You can see that it does take some time for payers to establish coverage policies, and so that in and of itself is also a curve. What we're doing with our market access team and Jen, is we really want to try to have those payer coverage policies established early in the launch, recognizing that some will come online early and some may take a quarter or two quarters or three quarters to establish a policy.

Annabel Samimy
Analyst, Stifel

Okay, great. Moving on to pricing. You've set, I guess, a range for all of us for some time of between $100,000 and $200,000 per year. Since then, you've had pretty phenomenal phase III data. Our own work, we've had some pretty positive feedback from payers suggesting that you could potentially price at the higher end of the range. How are you thinking about pricing today? Has the bar moved at all? Do you think that this is an environment where you can push the limits on pricing?

Wes Kaupinen
CEO, Palvella Therapeutics

Sure. We were pleased to see that your third-party payer research lined up with the payer research that we've conducted over time. We've established a pricing range of $100,000-$200,000 per patient per year. We're going to do a lot more payer work leading into launch to understand what the price point is. We've looked at orphan analogs in addition to the pricing research. We think that's the right range at this point in time, and look forward to updating everyone in February, hopefully, when we're at the point of FDA approval.

Annabel Samimy
Analyst, Stifel

Maybe we can touch on the compounding for anyone who's still confused about whether compounding is going to result in a step-through for you. Maybe you want to talk about that a little bit just to, I guess, lay out how physicians see compounding.

Wes Kaupinen
CEO, Palvella Therapeutics

Sure. Specifically on the step-throughs, we tested for that, Annabel, in our most recent payer research. There is nothing that is FDA approved for microcystic lymphatic malformation, so our payer research was conclusive that we would not expect a step-through through an interventional procedure or any sort of off-label pharmacologic therapy that may be out there. Our market research, as we mentioned, the greater than 70%, greater than 75%, it consistently points to physicians' clear desire for an FDA-approved therapy that has undergone rigorous testing in prospective clinical trials, which we have done in both phase II and phase III. We think that the market will gravitate towards the FDA-approved therapy very quickly.

Annabel Samimy
Analyst, Stifel

Okay, great. Any questions on mLM before I move on to cVM? No. Okay, talk to us about cVM. How is this similar, different, and what can we expect for this development program?

Wes Kaupinen
CEO, Palvella Therapeutics

Great. Cutaneous venous malformations are also a serious, rare genetic disease for which there are no FDA-approved therapies. The genetics are well-known. This is driven by either TIE2 or PIK3CA. It can upregulate the mTOR pathway, so the mTOR pathway is really driving the disease, which makes it a great target for QTORIN rapamycin. One of the things we think, Annabel, that is underappreciated about cVM is the size of the market opportunity. All of our market research points to an estimated greater than 75,000 patients in the United States with this disease. It is the most common type of vascular malformation, and it is treated largely in these vascular anomaly centers by the same physicians who we believe are treating microcystic lymphatic malformations. When we are at the point of FDA approval, we do expect a lot of synergy from a call point perspective.

From a development plan perspective, we want to start our phase III study this quarter before the end of the year. We are going to initiate that phase III based on the success of the phase II outcome, where we saw 73% of patients on our cutaneous venous malformation investigator global assessment report improvement. Two-thirds were either much or very much improved. We think again here that this lines up strategically nicely to the Palvella ethos of having the opportunity to be first in a serious rare disease where nothing is approved. Our approval timelines, we estimate will be in 2029, which I think is really key as we are launching in microcystic LM FDA approval in 2027, to be able to expand that label for QTORIN rapamycin into a much larger commercial indication is really core to our pipeline and our product thesis for QTORIN rapamycin.

Annabel Samimy
Analyst, Stifel

Okay, great. Just talking about the trial design, FDA just recently had a hearing on rare disease trial designs. Is there anything that you could take from that hearing and perhaps apply it to your favor with these programs?

Wes Kaupinen
CEO, Palvella Therapeutics

Yeah, absolutely. I think what we've seen from the recent hearing that you referenced is very encouraging to all of us who are rare disease drug developers. It's a recognition of the unmet need in rare diseases. The numbers range from seven to 10,000 rare diseases, still of which 95% don't have a single FDA-approved treatment. I think what the FDA said in that hearing was really that some of the provisions that apply for more common conditions and the way that you would develop drugs for more common conditions maybe aren't necessarily applicable for rare diseases. The term flexibility has been used to describe rare disease drug development program, regulatory flexibility.

In some cases, that's been the exception for rare disease, and I think there's a movement to not make that the exception, but rather really to make it the norm while in no way lowering that bar for safety, efficacy, and quality, which is absolutely critical for patients.

Annabel Samimy
Analyst, Stifel

Okay. Can you talk about what your timelines right now? What is the base case assumption for cVM as far as what the trial design is and how is that impacting the timelines? Do we see upside there potentially?

Wes Kaupinen
CEO, Palvella Therapeutics

Sure. Our base case, we're in the midst of our FDA interactions now and will soon be in a position to announce our study design, announce our primary endpoint, sample size. We've looked at a range of different outcomes. We think in each of those cases, we can enroll a pivotal study, read out that study, file for FDA approval. That would be via a supplemental NDA submission or an sNDA, and be FDA approved in that 2029 time period.

Annabel Samimy
Analyst, Stifel

Okay. Just to lay out how efficient your platform is, you have another trial ongoing in angiokeratomas. Can you talk to us about that trial? How is that recruitment going? Does it sit pretty much in the same vascular anomaly centers that you have for mLM and cVM?

Wes Kaupinen
CEO, Palvella Therapeutics

Yes. Clinically significant angiokeratomas are a type of lymphatic malformation. They present more superficially, so on the outside of the skin. They share some biological features with microcystic lymphatic malformations. More recently, the mTOR pathway has been shown, and VEGF pathway as well, to really be a key driver of that disease. So we think it's very synergistic with what we're doing in microcystic lymphatic malformations, cutaneous venous malformations. These patients can bleed with even minor friction to their disease. The disease can often present in the genitalia as well, so very debilitating to quality of life, and there's no FDA-approved therapies. Our ongoing phase II program is enrolling 10- 15 patients. We anticipate that that study will read out in the second half of next year, and we were really pleased that the FDA has already granted this program a fast-track designation.

We're looking forward to what we think is a major readout in the second half of next year. These patients often, because it's a lymphatic malformation, are treated in vascular anomaly centers. So, yet another opportunity to have some synergies with this commercial team that we're building. This commercial infrastructure, of course, is being built not for one product and one disease, but as you've drawn out here, we're building this commercial infrastructure to launch QTORIN rapamycin eventually in multiple indications, but also be able to bring on additional cutaneous products.

Annabel Samimy
Analyst, Stifel

Sorry, just you mentioned that it also potentially has VEGF involvement. Do you have any idea of the balance between the dependence on VEGF versus mTOR, and how that, I guess, multifaceted disease pathway might impact the potential outcome?

Wes Kaupinen
CEO, Palvella Therapeutics

Yeah. What we know about the pharmacology of rapamycin is that it acts on both of those pathways. We think QTORIN rapamycin, just like it is for microcystic lymphatic malformations and cutaneous venous malformations, is really addressing that causal biology.

Annabel Samimy
Analyst, Stifel

Okay, great. You're also going to announce a fourth indication.

Wes Kaupinen
CEO, Palvella Therapeutics

Yes.

Annabel Samimy
Analyst, Stifel

I guess, that begs the question, how many indications do you need for, or potentially need for a broad label? Is there a certain number that the FDA usually likes to see before they grant QTORIN rapamycin a broad label for mTOR-mediated diseases?

Wes Kaupinen
CEO, Palvella Therapeutics

Great question. We are going to announce a fourth indication. That will be before year-end. We expect this to be an mTOR-driven skin disease that is serious, rare, and where there is nothing approved, and that it is commercially attractive. What we mean by that is we focus on rare diseases that have meaningful existing prevalences. We are not focused on ultra-rare diseases. From a strategy perspective in terms of how we build out this pipeline in a product, we think the best approach is to run these programs and make them indication-specific, develop clinical data in each indication. With microcystic lymphatic malformations, very compelling evidence base from our phase II and phase III. We have seen that in cVM in phase II. So, we think that is the best strategy long-term for patients and long-term adoption. There could be a play in the future where we do more of a basket approach.

That is not contemplated with this fourth indication. That is going to be indication-specific. But as we have all seen from the publications from authors such as Dr. Paller, Fogel, and Dr. Swarbrick, there are dozens of diseases that are thought to be skin diseases driven by this mTOR pathway. We may, in the midterm and long- term, look at more of a basket-type approach. But for this quarter, we will be running an indication-specific program with this new announcement.

Annabel Samimy
Analyst, Stifel

Okay, great. I am not leaving much time for QTORIN pitavastatin, but maybe you can describe that program and DSAP. I am not going to try to remember what DSAP stands for. You can do that for us.

Wes Kaupinen
CEO, Palvella Therapeutics

Absolutely. DSAP, we say is an excellent disease for Palvella to step in and try to be the leaders and bring forward the first approved therapy. DSAP is disseminated superficial actinic porokeratosis.

Annabel Samimy
Analyst, Stifel

I would have totally gotten that wrong.

Wes Kaupinen
CEO, Palvella Therapeutics

This is a genetic disease where the biology is well-known. Patients have pruritic and premalignant lesions that can become squamous cell carcinomas, so there really is an urgency to treat these. There's no FDA-approved therapies. Historically, this is not an indication where there's been any work by industry, so we want to change that treatment paradigm. Really, the breakthrough here on the biology side over the last few years is a better understanding, is that this disease is caused by buildup of toxic intermediates as a result of a dysfunction and a genetic mutation in the mevalonate pathway. What we know is that we can inhibit that pathway upstream of the genetic defect through the use of statins, which are mevalonate pathway inhibitors. We applied the QTORIN platform here. We actually looked at seven different mevalonate pathway inhibitors, evaluating things like potency, skin pharmacokinetics, and stability.

The program that emerged as the best molecule to pair with QTORIN is called pitavastatin. Our plan is to start a phase II study in DSAP. We call this a pathogenesis-directed therapy because it's really getting to that causal biology in DSAP. Most recently, there was some data that was published. When we announced the program, we estimated there were more than 50,000 patients in the United States. There was some claims analysis work that's been done looking at the claims code there, which is L56.5, that showed there may be as many as 150,000 patients with DSAP. We're very excited by this program. It's the second product candidate from the QTORIN platform.

We'll announce a third product candidate from the QTORIN platform this quarter, and really, the goal is to continue to leverage this platform, which is an internal product development engine, to bring forward new therapies for patients with these rare skin diseases, vascular malformations, while we're shaping an exceptional launch for the microcystic lymphatic malformation community with QTORIN rapamycin.

Annabel Samimy
Analyst, Stifel

Great. And just cash runway with possibly three programs, multiple clinical trials while you are launching a commercial product?

Wes Kaupinen
CEO, Palvella Therapeutics

Sure. Thanks to our shareholders, we raised a $230 million equity financing in Q1 of this year. We ended the last quarter with about $236 million in cash. We have a very strong balance sheet deep into the QTORIN rapamycin for mLM launch, with a potential pathway to break even. Again, our goal is to remain very capital efficient, and make sure that our capital allocation decisions are evaluated very closely and do right by both our patients, but also our shareholders as well.

Annabel Samimy
Analyst, Stifel

Great. Right on time.

Wes Kaupinen
CEO, Palvella Therapeutics

Great. Thanks, Annabel.

Annabel Samimy
Analyst, Stifel

Thank you. Appreciate it.